Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Criteria

Inclusion Criteria:

• The subject was randomized into Study M10-346 and completed the study.

• Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.

• Male subjects must agree to comply with applicable contraceptive requirements.

• The subject is judged to be in generally good health.

Exclusion Criteria:

• The subject has taken any ADHD medication between the last dose of study drug in Study M10-346 and the first dose of study drug in the current study.

• The subject anticipates a move outside the geographic area.